How effective is Lazertinib in the treatment of EGFR mutated lung cancer?

Lazertinib is a new third-generation targeted drug mainly targeted at patients with non-small cell lung cancer (NSCLC) carrying EGFR mutations, especially those who have lost efficacy to first- and second-generation EGFR inhibitors due to the drug-resistant mutation T790M. With the rise of precision medicine, lanzetinib has attracted much attention in the field of lung cancer treatment due to its good efficacy and safety. This article will introduce in detail the mechanism of action, clinical efficacy, drug resistance issues and safety of lanzetinib.
First of all, as a third-generation EGFR tyrosine kinase inhibitor (TKI), lanzetinib can selectively target sensitive EGFR mutations (such as exon 19 deletion and 21 L858R point mutation) and T790M resistance mutations. This enables Lanzertinib to overcome the resistance problem caused by the T790M mutation of the first two generations of EGFR-TKI and restore the sensitivity of tumor cells to targeted therapy. In addition, lanzetinib has good brain penetration and is particularly effective in patients with brain metastases.

Clinical study data show that lanzatinib exhibits significant anti-tumor activity in patients with EGFR mutation-positive lung cancer. According to a multicenter phase II clinical trial, among patients carrying the T790M mutation, the objective response rate (ORR) of lanzutinib exceeded 50%, the disease control rate (DCR) reached more than 90%, and the median progression-free survival (PFS) reached more than 9 months. This data demonstrates that lanzetinib has a significant advantage in prolonging the time patients are free from disease progression and helps patients achieve a better quality of life.

For patients with brain metastases, the performance of lanzetinib is equally impressive. Due to its excellent central nervous system penetration ability, some patients with brain metastases have seen their brain lesions shrink significantly or even disappear after treatment with lanzertinib. The effect of controlling brain metastases is significantly better than traditional EGFR-TKI drugs. This feature makes lanzetinib an ideal choice for lung cancer patients with brain metastases.
Despite the remarkable efficacy of lanzetinib, drug resistance remains a clinical challenge. As the treatment time is prolonged, new resistance mechanisms may appear in some patients, such as C797S mutation or MET amplification, resulting in a decrease in the efficacy of lanzetinib. In response to this situation, current research is actively exploring combination treatment options, such as combined application with MET inhibitors, immunotherapy, etc., in order to delay the occurrence of drug resistance and improve the treatment effect.
In terms of safety, lanzetinib was generally well tolerated. Common adverse reactions include rash, diarrhea, mild liver function abnormalities and fatigue, most of which are mild to moderate and can be relieved by symptomatic treatment. Compared with first- and second-generation EGFR-TKIs, lanzetinib has a lower incidence of toxic side effects and a relatively better quality of life for patients. During treatment, patients need to regularly monitor liver function and electrocardiogram to prevent potential serious adverse events.
In general, as a third-generation targeted drug for EGFR-mutated lung cancer, lanzatinib has become an important treatment option for patients with EGFR mutations, especially T790M-positive patients, due to its significant efficacy, good ability to control brain metastases and good safety. In the future, with the development of more clinical studies and the improvement of combination drug strategies, lanzitinib is expected to bring longer survival and higher quality of life to more lung cancer patients.
Reference: https://www.drugs.com/